Non-vitamin K oral anticoagulants (NOACs, namely dabigatran, rivaroxaban, apixaban, and edoxaban) have been widely recommended in preventing thromboembolic events among adult patients with atrial fibrillation [1], or treating acute venous thromboembolism in adults [2]. In addition, the use of NOACs in the specified population (e.g., cancer, dialysis, hypertrophic cardiomyopathy, frailty, extremes of body weight, elderly) is also examined, consistently supporting its effectiveness and safety in stroke prevention.
